The SURMOUNT-5 clinical trial published in The New England Journal of Medicine showed that Zepbound (tirzepatide) achieved an average weight loss of 20.2% compared to 13.7% with Wegovy (semaglutide) at 72 weeks
Analysis based on publicly available information from the OzemPatches website, observed on December 26, 2025
Best For: Patients with a BMI of 30 or higher (or 27+ with weight-related health conditions) Those seeking maximum weight loss results People who prefer once-weekly dosing Patients without type 2 diabetes who need dedicated weight management What to Know: Wegovy follows a gradual dose escalation schedule over 16-20 weeks
Type 2 diabetes mellitus (T2DM) is one of the major subtypes of DM, and its pathogenesis is more complex, involving insulin resistance and insulin secretion dysfunction (Xourafa et al., 2024)
helps curb food cravings and supports feeling full longer.* CLINICALLY STUDIED NUTRIENTS & BOTANICAL EXTRACTS | GLP-Activate is formulated with clinically researched ingredients that support metabolic wellness and may support natural GLP pathways
doi:10.1152/ajpendo.2001.281.1.E155 Garber AJ